Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
Sales | 683,971 | 565,748 | 573,463 | 535,955 | 562,049 |
Gross Profit | 683,971 | 565,748 | 573,463 | 535,955 | 562,049 |
Operating Expenses | 204,999 | 1,048,403 | 381,253 | 158,163 | 342,331 |
Operating Income | 478,972 | -482,655 | 192,210 | 377,792 | 219,718 |
Interest Expense | 46,950 | 46,955 | 46,977 | 46,966 | 47,063 |
Other Income | 77,067 | -80,420 | 75,181 | 160,771 | -44,572 |
Pre-tax Income | 509,089 | -610,030 | 220,414 | 491,597 | 128,083 |
Net Income Continuous | 509,089 | -610,030 | 220,414 | 491,597 | 128,083 |
Minority Interests | 168,334 | -153,946 | 77,763 | 187,093 | 76,322 |
Net Income | $340,755 | $-456,084 | $142,651 | $304,504 | $51,761 |
EPS Basic Total Ops | 0.76 | -1.04 | 0.32 | 0.70 | 0.12 |
EPS Basic Continuous Ops | 1.14 | -1.40 | 0.50 | 1.13 | 0.30 |
EPS Diluted Total Ops | 0.76 | -1.04 | 0.32 | 0.70 | 0.12 |
EPS Diluted Continuous Ops | 0.84 | -0.86 | 0.36 | 0.81 | 0.21 |
EPS Diluted Before Non-Recurring Items | 1.60 | 1.56 | 0.73 | N/A | N/A |
EBITDA(a) | $484,296 | $-477,325 | $197,553 | $383,132 | $230,731 |